Literature DB >> 32133153

Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations.

Yanan Cao1, Lin Li1, Zhimin Feng1, Shengqing Wan1, Peide Huang1, Xiaohui Sun1, Fang Wen1, Xuanlin Huang1, Guang Ning1, Weiqing Wang1.   

Abstract

Entities:  

Keywords:  Bioinformatics; Genomic analysis

Year:  2020        PMID: 32133153      PMCID: PMC7040011          DOI: 10.1038/s41421-020-0147-1

Source DB:  PubMed          Journal:  Cell Discov        ISSN: 2056-5968            Impact factor:   10.849


× No keyword cloud information.
Dear Editor, The ACE2 gene encodes the angiotensin-converting enzyme-2, which has been proved to be the receptor for both the SARS-coronavirus (SARS-CoV) and the human respiratory coronavirus NL63. Recent studies and analyses indicate that ACE2 could be the host receptor for the novel coronavirus 2019-nCoV/SARS-CoV-2[1,2]. Previous studies demonstrated the positive correlation of ACE2 expression and the infection of SARS-CoV in vitro[3,4]. A number of ACE2 variants could reduce the association between ACE2 and S-protein in SARS-CoV or NL63[5]. Therefore, the expression level and expression pattern of human ACE2 in different tissues might be critical for the susceptibility, symptoms, and outcome of 2019-nCoV/SARS-CoV-2 infection. A recent single-cell RNA-sequencing (RNA-seq) analysis indicated that Asian males may have higher expression of ACE2[6]. Currently, the clinical reports of 2019-nCoV/SARS-CoV-2 infection from non-Asian populations for comparison are very limited. A study from Munich reported four German cases, all of which showed mild clinical symptoms without severe illness[7]. However, the genetic basis of ACE2 expression and function in different populations is still largely unknown. Therefore, genetic analysis of expression quantitative trait loci (eQTLs)[8] and potential functional coding variants in ACE2 among populations are required for further epidemiological investigations of 2019-nCoV/SARS-CoV-2 spreading in East Asian (EAS) and other populations. To systematically investigate the candidate functional coding variants in ACE2 and the allele frequency (AF) differences between populations, we analyzed all the 1700 variants (Supplementary Table S1) in ACE2 gene region from the ChinaMAP (China Metabolic Analytics Project, under reviewing) and 1KGP (1000 Genomes Project)[9] databases. The AFs of 62 variants located in the coding regions of ACE2 in ChinaMAP, 1KGP, and other large-scale genome databases were summarized (Supplementary Table S2). All of the 32 variants potentially affecting the amino acid sequence of ACE2 in databases were shown (Fig. 1a). Previous study showed that the residues near lysine 31, and tyrosine 41, 82–84, and 353–357 in human ACE2 were important for the binding of S-protein in coronavirus[5]. The mutations in these residues were not found in different populations in our study. Only a singleton truncating variant of ACE2 (Gln300X) was identified in the ChinaMAP (Fig. 1a). These data suggested that there was a lack of natural resistant mutations for coronavirus S-protein binding in populations. The effects of low-frequency missense variants in populations for S-protein binding could be further investigated. The distributions of seven hotspot variants (Lys26Arg, Ile468Val, Ala627Val, Asn638Ser, Ser692Pro, Asn720Asp, and Leu731Ile/Leu731Phe) in different populations were shown (Fig. 1b). Six low-frequency loci (rs200180615, rs140473595, rs199951323, rs147311723, rs149039346, and rs73635825) were found to be specific in 1KGP database, the AFs of which were also low in the gnomAD and TopMed[10] database. Only two of these six variants (rs200180615 and rs140473595) could be found in CHB (Han Chinese in Beijing) population with the AF < 0.01. Interestingly, the SNP rs2285666 with the highest AF in the 62 variants exhibited much higher AF in the ChinaMAP (0.556) and CHS (Han Chinese South, 0.557) populations compared to others (AMR, Ad Mixed American, 0.336; AFR, African, 0.2114; EUR, European, 0.235). In addition, the homozygous mutation rate in males (0.550) was much higher than females (0.310) in the Chinese population (Supplementary Table S2). Taken together, the differences in AFs of ACE2 coding variants among different populations suggested that the diverse genetic basis might affect ACE2 functions among populations.
Fig. 1

The coding-region variants and eQTL variants for ACE2 in East Asian and other populations.

a Schematics of 32 coding variants in ACE2 identified in the ChinaMAP and 1KGP databases. Yellow stars indicate the nonsense variants; dots indicate the missense variants. The number of samples with hotspot variants was marked. b The distribution of hotspot missense mutations of ACE2 in different populations. The colors indicate different populations. c The distribution and the allele frequencies of representative eQTL variants for ACE2 in different populations. Pie charts depict the allele frequencies of an intron variant of ACE2 (rs4646127) in the world. Orange color denotes the frequency of alteration allele, and blue color denotes the reference allele. The allele frequencies of 15 eQTLs for ACE2 gene are shown in tables. The color gradient from blue to red indicates the increasing of allele frequencies. The allele frequencies of INDEL variant rs200781818 were annotated by the gnomAD database. EAS, East Asian; EUR, European; AFR, African; SAS, South Asian; AMR, Ad Mixed American.

The coding-region variants and eQTL variants for ACE2 in East Asian and other populations.

a Schematics of 32 coding variants in ACE2 identified in the ChinaMAP and 1KGP databases. Yellow stars indicate the nonsense variants; dots indicate the missense variants. The number of samples with hotspot variants was marked. b The distribution of hotspot missense mutations of ACE2 in different populations. The colors indicate different populations. c The distribution and the allele frequencies of representative eQTL variants for ACE2 in different populations. Pie charts depict the allele frequencies of an intron variant of ACE2 (rs4646127) in the world. Orange color denotes the frequency of alteration allele, and blue color denotes the reference allele. The allele frequencies of 15 eQTLs for ACE2 gene are shown in tables. The color gradient from blue to red indicates the increasing of allele frequencies. The allele frequencies of INDEL variant rs200781818 were annotated by the gnomAD database. EAS, East Asian; EUR, European; AFR, African; SAS, South Asian; AMR, Ad Mixed American. To analyze the distribution of eQTLs for ACE2, we used the Genotype Tissue Expression (GTEx) database (https://www.gtexportal.org/home/datasets). We found 15 unique eQTL variants (14 SNPs and 1 INDELs) for ACE2 with q value ≤ 0.05 in 20 tissues from the GTEx database (rs112171234, rs12010448, rs143695310, rs1996225, rs200781818, rs2158082, rs4060, rs4646127, rs4830974, rs4830983, rs5936011, rs5936029, rs6629110, rs6632704, and rs75979613). The AFs of the 15 eQTL variants were compared among different populations. Notably, our results showed most of the 15 eQTL variants had much higher AFs in the ChinaMAP dataset and EAS populations compared to European populations (Fig. 1c and Supplementary Table S3). The AFs of the top 6 common variants (rs4646127, rs2158082, rs5936011, rs6629110, rs4830983, and rs5936029) were higher than 95% in EAS populations, whereas the AFs of these variants in European populations were much lower (52%–65%). All of the 11 common variants (AF > 0.05) and 1 rare variant (rs143695310) in the 15 eQTLs are associated with high expression of ACE2 in tissues (Supplementary Table S3). For instance, the eQTL variant rs4646127 (log allelic fold change = 0.314), which locates in the intron of ACE2 gene, has the highest AFs in both of the ChinaMAP (0.997) and EAS (0.994) populations. Comparatively, the AFs of rs4646127 in EUR (0.651) and AMR (0.754) populations are much lower. These findings suggested the genotypes of ACE2 gene polymorphism may be associated higher expression levels of ACE2 in EAS population. Recent reports of the ACE2 expression analysis in lung tissues from Asian and Caucasian populations are still controversial. The single-cell RNA-seq analysis reported that the Asian donor had much higher ACE2 expression cell ratio than white and African-American donors[6]. In contrast, the ACE2 expression analysis using the RNA-seq and microarray datasets from control lung tissues indicated there were no significant differences between Asian and Caucasian, or male and female[11]. The ACE2-expressing cells are a very small part of cells in lung tissues[6]. The sample size and the purity of ACE2-positive cells in the selected samples would influence the conclusions. Our analysis showed the differences in distribution and AFs of eQTLs for ACE2 in different populations, indicating the diversity of ACE2 expression pattern in populations (Supplementary Table S3). Large-scale and multiple tissue-level analysis of single-cell RNA-seq would be more accurate for the expression analysis of ACE2 in different populations. In addition, our data showed the moderate difference in AFs of eQTLs between South Asian and EAS, which suggests the potential difference of ACE2 expression in different populations and ethnics in Asia (Fig. 1c). In summary, we systematically analyzed coding-region variants in ACE2 and the eQTL variants, which may affect the expression of ACE2 using the GTEx database to compare the genomic characteristics of ACE2 among different populations. Our findings indicated that no direct evidence was identified genetically supporting the existence of coronavirus S-protein binding-resistant ACE2 mutants in different populations (Fig. 1a). The data of variant distribution and AFs may contribute to the further investigations of ACE2, including its roles in acute lung injury and lung function[12]. The East Asian populations have much higher AFs in the eQTL variants associated with higher ACE2 expression in tissues (Fig. 1c), which may suggest different susceptibility or response to 2019-nCoV/SARS-CoV-2 from different populations under the similar conditions. Supplementary Table S1 Supplementary Table S2 Supplementary Table S3
  10 in total

1.  Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans.

Authors: 
Journal:  Science       Date:  2015-05-07       Impact factor: 47.728

2.  The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.

Authors:  Wenhui Li; Jianhua Sui; I-Chueh Huang; Jens H Kuhn; Sheli R Radoshitzky; Wayne A Marasco; Hyeryun Choe; Michael Farzan
Journal:  Virology       Date:  2007-07-12       Impact factor: 3.616

3.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.

Authors:  Wenhui Li; Chengsheng Zhang; Jianhua Sui; Jens H Kuhn; Michael J Moore; Shiwen Luo; Swee-Kee Wong; I-Chueh Huang; Keming Xu; Natalya Vasilieva; Akikazu Murakami; Yaqing He; Wayne A Marasco; Yi Guan; Hyeryun Choe; Michael Farzan
Journal:  EMBO J       Date:  2005-03-24       Impact factor: 11.598

4.  A global reference for human genetic variation.

Authors:  Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis
Journal:  Nature       Date:  2015-10-01       Impact factor: 49.962

5.  A pneumonia outbreak associated with a new coronavirus of probable bat origin.

Authors:  Peng Zhou; Xing-Lou Yang; Xian-Guang Wang; Ben Hu; Lei Zhang; Wei Zhang; Hao-Rui Si; Yan Zhu; Bei Li; Chao-Lin Huang; Hui-Dong Chen; Jing Chen; Yun Luo; Hua Guo; Ren-Di Jiang; Mei-Qin Liu; Ying Chen; Xu-Rui Shen; Xi Wang; Xiao-Shuang Zheng; Kai Zhao; Quan-Jiao Chen; Fei Deng; Lin-Lin Liu; Bing Yan; Fa-Xian Zhan; Yan-Yi Wang; Geng-Fu Xiao; Zheng-Li Shi
Journal:  Nature       Date:  2020-02-03       Impact factor: 69.504

6.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding.

Authors:  Roujian Lu; Xiang Zhao; Juan Li; Peihua Niu; Bo Yang; Honglong Wu; Wenling Wang; Hao Song; Baoying Huang; Na Zhu; Yuhai Bi; Xuejun Ma; Faxian Zhan; Liang Wang; Tao Hu; Hong Zhou; Zhenhong Hu; Weimin Zhou; Li Zhao; Jing Chen; Yao Meng; Ji Wang; Yang Lin; Jianying Yuan; Zhihao Xie; Jinmin Ma; William J Liu; Dayan Wang; Wenbo Xu; Edward C Holmes; George F Gao; Guizhen Wu; Weijun Chen; Weifeng Shi; Wenjie Tan
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany.

Authors:  Camilla Rothe; Mirjam Schunk; Peter Sothmann; Gisela Bretzel; Guenter Froeschl; Claudia Wallrauch; Thorbjörn Zimmer; Verena Thiel; Christian Janke; Wolfgang Guggemos; Michael Seilmaier; Christian Drosten; Patrick Vollmar; Katrin Zwirglmaier; Sabine Zange; Roman Wölfel; Michael Hoelscher
Journal:  N Engl J Med       Date:  2020-01-30       Impact factor: 91.245

8.  Angiotensin-converting enzyme 2 protects from severe acute lung failure.

Authors:  Yumiko Imai; Keiji Kuba; Shuan Rao; Yi Huan; Feng Guo; Bin Guan; Peng Yang; Renu Sarao; Teiji Wada; Howard Leong-Poi; Michael A Crackower; Akiyoshi Fukamizu; Chi-Chung Hui; Lutz Hein; Stefan Uhlig; Arthur S Slutsky; Chengyu Jiang; Josef M Penninger
Journal:  Nature       Date:  2005-07-07       Impact factor: 49.962

9.  Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor.

Authors:  Heike Hofmann; Martina Geier; Andrea Marzi; Mandy Krumbiegel; Matthias Peipp; Georg H Fey; Thomas Gramberg; Stefan Pöhlmann
Journal:  Biochem Biophys Res Commun       Date:  2004-07-09       Impact factor: 3.575

10.  Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.

Authors:  Daniel Taliun; Daniel N Harris; Michael D Kessler; Jedidiah Carlson; Zachary A Szpiech; Raul Torres; Sarah A Gagliano Taliun; André Corvelo; Stephanie M Gogarten; Hyun Min Kang; Achilleas N Pitsillides; Jonathon LeFaive; Seung-Been Lee; Xiaowen Tian; Brian L Browning; Sayantan Das; Anne-Katrin Emde; Wayne E Clarke; Douglas P Loesch; Amol C Shetty; Thomas W Blackwell; Albert V Smith; Quenna Wong; Xiaoming Liu; Matthew P Conomos; Dean M Bobo; François Aguet; Christine Albert; Alvaro Alonso; Kristin G Ardlie; Dan E Arking; Stella Aslibekyan; Paul L Auer; John Barnard; R Graham Barr; Lucas Barwick; Lewis C Becker; Rebecca L Beer; Emelia J Benjamin; Lawrence F Bielak; John Blangero; Michael Boehnke; Donald W Bowden; Jennifer A Brody; Esteban G Burchard; Brian E Cade; James F Casella; Brandon Chalazan; Daniel I Chasman; Yii-Der Ida Chen; Michael H Cho; Seung Hoan Choi; Mina K Chung; Clary B Clish; Adolfo Correa; Joanne E Curran; Brian Custer; Dawood Darbar; Michelle Daya; Mariza de Andrade; Dawn L DeMeo; Susan K Dutcher; Patrick T Ellinor; Leslie S Emery; Celeste Eng; Diane Fatkin; Tasha Fingerlin; Lukas Forer; Myriam Fornage; Nora Franceschini; Christian Fuchsberger; Stephanie M Fullerton; Soren Germer; Mark T Gladwin; Daniel J Gottlieb; Xiuqing Guo; Michael E Hall; Jiang He; Nancy L Heard-Costa; Susan R Heckbert; Marguerite R Irvin; Jill M Johnsen; Andrew D Johnson; Robert Kaplan; Sharon L R Kardia; Tanika Kelly; Shannon Kelly; Eimear E Kenny; Douglas P Kiel; Robert Klemmer; Barbara A Konkle; Charles Kooperberg; Anna Köttgen; Leslie A Lange; Jessica Lasky-Su; Daniel Levy; Xihong Lin; Keng-Han Lin; Chunyu Liu; Ruth J F Loos; Lori Garman; Robert Gerszten; Steven A Lubitz; Kathryn L Lunetta; Angel C Y Mak; Ani Manichaikul; Alisa K Manning; Rasika A Mathias; David D McManus; Stephen T McGarvey; James B Meigs; Deborah A Meyers; Julie L Mikulla; Mollie A Minear; Braxton D Mitchell; Sanghamitra Mohanty; May E Montasser; Courtney Montgomery; Alanna C Morrison; Joanne M Murabito; Andrea Natale; Pradeep Natarajan; Sarah C Nelson; Kari E North; Jeffrey R O'Connell; Nicholette D Palmer; Nathan Pankratz; Gina M Peloso; Patricia A Peyser; Jacob Pleiness; Wendy S Post; Bruce M Psaty; D C Rao; Susan Redline; Alexander P Reiner; Dan Roden; Jerome I Rotter; Ingo Ruczinski; Chloé Sarnowski; Sebastian Schoenherr; David A Schwartz; Jeong-Sun Seo; Sudha Seshadri; Vivien A Sheehan; Wayne H Sheu; M Benjamin Shoemaker; Nicholas L Smith; Jennifer A Smith; Nona Sotoodehnia; Adrienne M Stilp; Weihong Tang; Kent D Taylor; Marilyn Telen; Timothy A Thornton; Russell P Tracy; David J Van Den Berg; Ramachandran S Vasan; Karine A Viaud-Martinez; Scott Vrieze; Daniel E Weeks; Bruce S Weir; Scott T Weiss; Lu-Chen Weng; Cristen J Willer; Yingze Zhang; Xutong Zhao; Donna K Arnett; Allison E Ashley-Koch; Kathleen C Barnes; Eric Boerwinkle; Stacey Gabriel; Richard Gibbs; Kenneth M Rice; Stephen S Rich; Edwin K Silverman; Pankaj Qasba; Weiniu Gan; George J Papanicolaou; Deborah A Nickerson; Sharon R Browning; Michael C Zody; Sebastian Zöllner; James G Wilson; L Adrienne Cupples; Cathy C Laurie; Cashell E Jaquish; Ryan D Hernandez; Timothy D O'Connor; Gonçalo R Abecasis
Journal:  Nature       Date:  2021-02-10       Impact factor: 69.504

  10 in total
  260 in total

1.  Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank.

Authors:  Zahra Raisi-Estabragh; Celeste McCracken; Mae S Bethell; Jackie Cooper; Cyrus Cooper; Mark J Caulfield; Patricia B Munroe; Nicholas C Harvey; Steffen E Petersen
Journal:  J Public Health (Oxf)       Date:  2020-08-18       Impact factor: 2.341

Review 2.  Microfluidic-based approaches for COVID-19 diagnosis.

Authors:  Hsuan-Yu Mu; Yu-Lun Lu; Tzu-Hung Hsiao; Jen-Huang Huang
Journal:  Biomicrofluidics       Date:  2020-12-08       Impact factor: 2.800

3.  Genetic variability in COVID-19-related genes in the Brazilian population.

Authors:  Rodrigo Secolin; Tânia K de Araujo; Marina C Gonsales; Cristiane S Rocha; Michel Naslavsky; Luiz De Marco; Maria A C Bicalho; Vinicius L Vazquez; Mayana Zatz; Wilson A Silva; Iscia Lopes-Cendes
Journal:  Hum Genome Var       Date:  2021-04-02

Review 4.  COVID-19 and androgen-targeted therapy for prostate cancer patients.

Authors:  Neil A Bhowmick; Jillian Oft; Tanya Dorff; Sumanta Pal; Neeraj Agarwal; Robert A Figlin; Edwin M Posadas; Stephen J Freedland; Jun Gong
Journal:  Endocr Relat Cancer       Date:  2020-09       Impact factor: 5.678

5.  A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives.

Authors:  Antonio Cassone; Donatella Gucciardo; Roberto Cauda
Journal:  Pathog Glob Health       Date:  2020-05-25       Impact factor: 2.894

6.  ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.

Authors:  Gomaa Mostafa-Hedeab
Journal:  Rep Biochem Mol Biol       Date:  2020-04

7.  Effects of the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) on the nervous system. What can we expect from SARS -CoV-2?

Authors:  Jeison Monroy-Gómez; Orlando Torres-Fernández
Journal:  Biomedica       Date:  2020-10-30       Impact factor: 0.935

8.  Prevalence of Chemosensory Dysfunction in COVID-19 Patients: A Systematic Review and Meta-analysis Reveals Significant Ethnic Differences.

Authors:  Christopher S von Bartheld; Molly M Hagen; Rafal Butowt
Journal:  ACS Chem Neurosci       Date:  2020-09-17       Impact factor: 4.418

9.  Decoding SARS-CoV-2 hijacking of host mitochondria in COVID-19 pathogenesis.

Authors:  Keshav K Singh; Gyaneshwer Chaubey; Jake Y Chen; Prashanth Suravajhala
Journal:  Am J Physiol Cell Physiol       Date:  2020-06-08       Impact factor: 4.249

Review 10.  Neurobiology of COVID-19.

Authors:  Majid Fotuhi; Ali Mian; Somayeh Meysami; Cyrus A Raji
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.